Effect of an ergoline derivate-nicergoline (Sermion®) on methylandrostenediol-induced hypertension in the rat

A. Molteni, P. A. Nickerson, A. C. Brownie, Kiang Liu

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The antihypertensive activity of nicergoline (Sermion®), an adrenolytic and vasodilator drug, was tested in rats when hypertensive vascular disease was induced by administration of methylandrostenediol (MAD). Nicergoline not only counteracted the effect of MAD on the systolic blood pressure of the rats, but it also prevented the appearance of vascular lesions usually induced by this type of experimental hypertension on arterioles of several organs such as heart, kidney and brain and of the pancreatic mesenteric region. When given alone, the drug was well tolerated. Since the drug did not interfere with the modification induced by MAD on the adrenal steroidogenesis, as seen by EM studies of the zona fasciculata of the androgen-treated animals, it is likely that it may have exerted its adrenolytic effect on the peripheral vessels of the MAD-induced hypertensive rats.

Original languageEnglish (US)
Pages (from-to)119-134
Number of pages16
JournalArchives Internationales de Pharmacodynamie et de Therapie
Volume247
Issue number1
StatePublished - Dec 1 1980

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Effect of an ergoline derivate-nicergoline (Sermion®) on methylandrostenediol-induced hypertension in the rat'. Together they form a unique fingerprint.

Cite this